Floatz logo

Durvalumab

Select Advanced Solid Tumors

MedImmune LLCmonoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Select Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
Atezolizumab
Immunocore Ltd
Phase 1/2CC
Tebentafusp
Immunocore Ltd
Phase 1/2CC
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 1/2CC
Ksq-004Ex
M.D. Anderson Cancer Center
Phase 1/2CC
HLA- A*0201-RESTRICTED NY-ESO-1- AND LAGE-1A-SPECIFIC SOLUBLE TCR/ANTI-CD3 BISPECIFIC MOLECULE
Immunocore Ltd
Phase 1/2CC

View all 12 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →